Last edition
News about "Alchemab series A funding"
Alchemab Launches First-in-Human Trial of ATLX-1282, Secures 32 Million USD Financing Boost
Alchemab Therapeutics, a biopharmaceutical company that develops naturally occurring therapeutic antibodies from resilient individuals, has announced the initiation of its first-in-human phase 1 study of ATLX-1282.
Alchemab Series A Funding | 10/09/2025 | By Darshana | 166
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members